Treatment of hyponatremia

Internal Medicine

Volumn 47, Issue 10, 2008, Pages 885-891

  Gross, Peter ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Hyponatremia; Vasopressin receptor antagonist

Indexed keywords

CONIVAPTAN; DEMECLOCYCLINE; ISOTONIC SOLUTION; LITHIUM CARBONATE; LIXIVAPTAN; LOOP DIURETIC AGENT; MOZAVAPTAN; PLACEBO; SATAVAPTAN; SODIUM; TOLVAPTAN; UREA; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN RECEPTOR;

CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DEHYDRATION; DIABETES INSIPIDUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; ELECTROLYTE DISTURBANCE; FLUID INTAKE; FLUID RETENTION; HEADACHE; HEART FAILURE; HUMAN; HYPONATREMIA; HYPOVOLEMIA; INCIDENCE; LIVER CIRRHOSIS; MENTAL DISEASE; NEPHROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; POLYURIA; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; UREMIA; WEAKNESS; XEROSTOMIA; DRUG ANTAGONISM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PLASMA VOLUME; SCHWARTZ BARTTER SYNDROME;

CLINICAL TRIALS AS TOPIC; HUMANS; HYPONATREMIA; HYPOVOLEMIA; INAPPROPRIATE ADH SYNDROME; PLASMA VOLUME; RECEPTORS, VASOPRESSIN; SODIUM;

EID: 45849115436     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0918     Document Type: Review

References (43)

1. Adrogué HJ, Madias NE. Hyponatremia. New Engl J Med 21: 1581-1589, 2000.
2. Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatremia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant 21: 70-76, 2006.
3. Renneboog B, Vendemergel X, Manto MN, et al. Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. Am J Med 119: 71e1-71e8, 2006.
4. Anderson RJ, Chung HM, Kluge R, et al. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 102: 164-168, 1985.
5. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 337: 169-172, 2003.
6. Heumann DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk of early death. Hepatology 40: 802-810, 2004.
7. Londono MC, Guevara M, Rimola A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 130: 1135-1143, 2006.
8. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme-inhibition in patients with severe chronic heart failure. Circulation 73: 257-267, 1986.
9. Goldberg A, Hammerman H, Petchersky S, et al. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Int Med 166: 781-786, 2006.
10. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. JAMA 297: 1319-1931, 2007.
11. Leaf A, Mamby AR. An antidiuretic mechanism not regulated by extracellular fluid toxicity. J Clin Invest 31: 60-71, 1952.
12. Weston RE, Grossman J, Borun ER, et al. The pathogenesis and treatment of hyponatremia in congestive heart failure. Am J Med 25: 558-572, 1958.
13. Gross PA, Anderson RJ. Effects of DDAVP and AVP on sodium- and water-balance in conscious rat. Am J Physiol 243: R512-R519, 1982.
14. Anderson RJ, Cadnapaphornchai P, Harbottle J, et al. Mechanism of effect of thoracic inferior vena cava constriction on renal water excretion. J Clin Invest 54: 1473-1479, 1974.
15. Linas SL, Anderson RJ, Guggenheim SJ, et al. Role of vasopressin in impaired water excretion in conscious rats with experimental cirrhosis. Kidney Int 20: 173-180, 1981.
16. Yaron M, Bennett CM. Mechanism of impaired water excretion in acute right ventricular failure in conscious dogs. Circ Res 42: 801-805, 1978.
17. Mandell IN, De Fronzo RA, Robertson GL, et al. Role of plasma arginine vasopressin in the impaired water diuresis of isolated glucocorticoid deficiency in the rat. Kidney Int 17: 186-195, 1980.
18. Flear CTG, Hilton P. Hyponatremia and severity and outcome of myocardial infarction. But Med J 1: 1242-1246, 1979.
19. Bichet D, Szatalowicz V, Chaimovitz C, et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 96: 413-417, 1982.
20. Skowsky WR, Kikucki TA. The role of vasopressin in the impaired water excretion of myxedema. Am J Med 64: 613-621, 1978.
21. Schrier RW, Berl T. Nonosmolar factors affecting renal water excretion. New England J Med 292: 81-87, 1975.
22. White MG, Fetner CD. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with lithium carbonate. New Engl J Med 292: 390-392, 1975.
23. Forrest JN Jr, Cox M, Hong C, et al. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. New Engl J Med 298: 178-177, 1978.
24. Juurlink DN, Mamdani MM, Kopp A, et al. Drug-induced lithium toxicity in the elderly;a population-based study. J Am Geriatr Soc 52: 794-798, 2004.
25. Verbalis JG. Adaptation to acute and chronic hyponatremia:implications for symptomatology, diagnosis and therapy. Semin Nephrol 18: 3-19, 1998.
26. Decaux G, Brimioulle S, Genette F, et al. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med 69: 99-106, 1980.
27. Hantman D, Rossier B, Zohlman R, et al. Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. An alternative treatment to hypertonic saline. Ann Intern Med 78: 870-876, 1973.
28. Manning M, Sawyer WH. Development of selective agonists and antagonists of vasopressin and oxytocin. In: Vasopressin. Schrier RW, Ed. Raven Press, New York, 1985: 131-144.
29. Burnier M, Waeber B, Nussberger J, et al. Cardiovascular effects of vascular antagonists (V1) to the action of vasopressin in health and diseases. In: Cowley AW, Liard JF, Ansiello DA, Eds. Vasopressin, Cellular and Integrative Functions. Raven Press, New York, 1988: 473-480.
30. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent OPC 31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 105: 787-791, 1992.
31. Yamamura Y, Ohnishi A, Orita Y, et al. Water diuresis induced by a nonpeptide vasopressin V-2 receptor antagonist, OPC-31260. In: Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research. Saito T, Kurokawa K, Yoshida S, Eds. Elsevier, Tokyo, 1995: 627-634.
32. Chan PS, Coupet J, Park HC, et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. In: Zingg HH, Bourque CW, Bichet DG, Eds. Vasopressin and Oxytocin; Molecular, Cellular and Clinical Advances. Raven Press, New York, 1998: 439-443.
33. Abraham WT, Shamshirsaz AA, Mc Fann K, et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional Class II and III chronic heart failure patients. J Am Coll Cardiol 47: 1615-1621, 2006.
34. Gerbes AL, Gülberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist:a randomized double-blind multicenter trial. Gastroenterology 124: 933-939, 2003.
35. Tahara A, Tomura Y, Wada K, et al. Pharmacological profile of YM 087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 282: 301-306, 1997.
36. Ghali JK, Verbalis JG, Gross P, et al. Vasopressin V1a and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure. J Am Soc Nephrol 16: 43 A, 2005 (abstract).
37. Serradeil-LeGal C, Lacour C, Valette G, et al. Characterisation of SR 121 463 A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 98: 2729-2738, 1996.
38. Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR 121 463 B, an orally active, nonpeptide, vasopressin V2 receptor antagonist. J Am Soc Nephrol 15: 563 A, 2004 (abstract).
39. Yamamura Y, Nakamura S, Itoh S, et al. OPC 41061, a highly potent human vasopressin V-2 receptor antagonist:pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287: 860-867, 1998.
40. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 291: 1963-1971, 2004.
41. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 97: 1064-1067, 2006.
42. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. JAMA 297: 1319-1331, 2007.
43. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, for hyponatremia. New Engl J Med 355: 2099-2112, 2006.